Advertisement

Massachusetts Institute of Technology and Children's Hospital Corp. accuse Shire Regenerative Medicine of willfully infringing on a trio of patents with its DermaGraft diabetic foot ulcer skin graft treatment.

legal gavel

Regenerative therapies maker Shire (NSDQ:SHPGY) found itself the focus of a lawsuit after the Massachusetts Institute of Technology and Children's Medical Center Corp. accused the company of willfully infringing on a trio of patents.

The plaintiffs claim Shire, Shire Regenerative Medicine and Shire Pharmaceuticals are in violation of 2 patents describing a "3 dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo," as well as a 3rd patent for preparation of such scaffolds.

Advertisement
Advertisement